drugset / Trial / NCT04874831
Domatinostat in Combination With Avelumab in Patients With Treatment-naïve Metastatic Merkel Cell Carcinoma (MERKLIN 1)
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial studies how well domatinostat (4SC-202) works in combination with avelumab in adult patients with treatment-naïve metastatic Merkel Cell Carcinoma
Timeline
- Start
- 2021-11-01
- Primary completion
- 2025-09
- Completion
- 2025-09
Outcome
Outcome not reported
Stopped: “Refocusing of sponsor's clinical development program. No safety concern or change of the risk-benefit assessment of the investigational medicinal product has led to this decision.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | — | — |
| Subject | Domatinostat | Small molecule | — | — |